Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial

Daisuke Yabe; Takashi Eto; Masanari Shiramoto; Shin Irie; Kenta Murotani; Yusuke Seino; Hitoshi Kuwata; Takeshi Kurose; Susumu Seino; Bo Ahrén; Yutaka Seino

doi:10.1111/dom.12817

Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12817 ◽

2016 ◽

Vol 19 (3) ◽

pp. 442-447 ◽

Cited By ~ 13

Author(s):

Daisuke Yabe ◽

Takashi Eto ◽

Masanari Shiramoto ◽

Shin Irie ◽

Kenta Murotani ◽

...

Keyword(s):

Type 2 Diabetes ◽

Physiological Response ◽

Receptor Agonist ◽

Open Label ◽

Exploratory Trial ◽

Japanese Subjects

Download Full-text

Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial

Diabetes Therapy ◽

10.1007/s13300-021-01014-0 ◽

2021 ◽

Vol 12 (3) ◽

pp. 863-877

Author(s):

Hiroaki Seino

Keyword(s):

Type 2 Diabetes ◽

Hepatic Dysfunction ◽

Single Site ◽

Efficacy And Safety ◽

Open Label ◽

Exploratory Trial

Download Full-text

Author response for "Superior efficacy with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese subjects with type 2 diabetes in a phase 3, open‐label, randomised trial"

10.1111/dom.13856/v2/response1 ◽

2019 ◽

Author(s):

Kohei Kaku ◽

Eiichi Araki ◽

Yukio Tanizawa ◽

Bue Ross Agner ◽

Tomoyuki Nishida ◽

...

Keyword(s):

Type 2 Diabetes ◽

Randomised Trial ◽

Fixed Ratio ◽

Insulin Degludec ◽

Author Response ◽

Open Label ◽

Phase 3 ◽

Superior Efficacy ◽

Japanese Subjects

Download Full-text

Review for "Superior efficacy with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese subjects with type 2 diabetes in a phase 3, open‐label, randomised trial"

10.1111/dom.13856/v1/review2 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomised Trial ◽

Fixed Ratio ◽

Insulin Degludec ◽

Open Label ◽

Phase 3 ◽

Superior Efficacy ◽

Japanese Subjects

Download Full-text

Review for "Superior efficacy with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese subjects with type 2 diabetes in a phase 3, open‐label, randomised trial"

10.1111/dom.13856/v2/review3 ◽

2019 ◽

Author(s):

Yoshifumi Saisho

Keyword(s):

Type 2 Diabetes ◽

Randomised Trial ◽

Fixed Ratio ◽

Insulin Degludec ◽

Open Label ◽

Phase 3 ◽

Superior Efficacy ◽

Japanese Subjects

Download Full-text

Review for "Superior efficacy with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese subjects with type 2 diabetes in a phase 3, open‐label, randomised trial"

10.1111/dom.13856/v2/review2 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomised Trial ◽

Fixed Ratio ◽

Insulin Degludec ◽

Open Label ◽

Phase 3 ◽

Superior Efficacy ◽

Japanese Subjects

Download Full-text

Correction to: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial

Diabetes Therapy ◽

10.1007/s13300-021-01123-w ◽

2021 ◽

Author(s):

Hiroaki Seino

Keyword(s):

Type 2 Diabetes ◽

Hepatic Dysfunction ◽

Single Site ◽

Efficacy And Safety ◽

Open Label ◽

Exploratory Trial

Download Full-text

Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study

Diabetes Therapy ◽

10.1007/s13300-018-0455-8 ◽

2018 ◽

Vol 9 (4) ◽

pp. 1549-1567 ◽

Cited By ~ 4

Author(s):

Hisamitsu Ishihara ◽

Susumu Yamaguchi ◽

Ikko Nakao ◽

Taishi Sakatani

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Japanese Patients ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, singl

Journal of Diabetes Investigation ◽

10.1111/jdi.12694 ◽

2017 ◽

Vol 9 (2) ◽

pp. 332-340 ◽

Cited By ~ 25

Author(s):

Yutaka Seino ◽

Daisuke Yabe ◽

Takashi Sasaki ◽

Atsushi Fukatsu ◽

Hisae Imazeki ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Fat Mass ◽

Receptor Agonist ◽

Japanese Patients ◽

Open Label ◽

Sodium Glucose Cotransporter ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Review for "Superior efficacy with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese subjects with type 2 diabetes in a phase 3, open‐label, randomised trial"

10.1111/dom.13856/v1/review3 ◽

2019 ◽

Author(s):

Johan Jendle

Keyword(s):

Type 2 Diabetes ◽

Randomised Trial ◽

Fixed Ratio ◽

Insulin Degludec ◽

Open Label ◽

Phase 3 ◽

Superior Efficacy ◽

Japanese Subjects

Download Full-text

Decision letter for "Superior efficacy with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese subjects with type 2 diabetes in a phase 3, open‐label, randomised trial"

10.1111/dom.13856/v3/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomised Trial ◽

Fixed Ratio ◽

Insulin Degludec ◽

Open Label ◽

Phase 3 ◽

Superior Efficacy ◽

Japanese Subjects

Download Full-text